LEADER 04083nam 2200685 450 001 9910139117603321 005 20200520144314.0 010 $a1-118-85586-8 010 $a1-118-85601-5 010 $a1-118-85604-X 035 $a(CKB)2550000001277691 035 $a(EBL)1676383 035 $a(SSID)ssj0001216013 035 $a(PQKBManifestationID)11647663 035 $a(PQKBTitleCode)TC0001216013 035 $a(PQKBWorkID)11190219 035 $a(PQKB)11590652 035 $a(OCoLC)880451437 035 $a(MiAaPQ)EBC1676383 035 $a(DLC) 2014006433 035 $a(Au-PeEL)EBL1676383 035 $a(CaPaEBR)ebr10862682 035 $a(CaONFJC)MIL599755 035 $a(OCoLC)878111053 035 $a(PPN)200125826 035 $a(EXLCZ)992550000001277691 100 $a20140501h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aHandbook of nanotoxicology, nanomedicine and stem cell use in toxicology /$fSaura C. Sahu, Daniel A. Casciano, editors 205 $aFirst edition. 210 1$aWest Sussex, England :$cJohn Wiley & Sons,$d2014. 210 4$dİ2014 215 $a1 online resource (441 p.) 300 $aDescription based upon print version of record. 311 $a1-118-43926-0 311 $a1-306-68504-4 320 $aIncludes bibliographical references and indexes. 327 $aHandbook of Nanotoxicology, Nanomedicine and Stem Cell Use in Toxicology; Contents; Contributors; Preface; Acknowledgments; Dedication; Abbreviations and Acronyms; Part One Nanotoxicology; Chapter 01 Testing Nanotoxicity: An Update of New and Traditional Methods; Chapter 02 Considerations for In Vitro Nanotoxicity Testing; Chapter 03 In Vivo Evaluation of Acute and Chronic Nanotoxicity; Chapter 04 Genotoxicity of Silver Nanoparticles; Chapter 05 Immunotoxicology of Nanomaterials; Chapter 06 Neurotoxicity of Nanoparticles 327 $aChapter 07 Nanoparticles and Plants: From Toxicity to Activation of GrowthChapter 08 Epigallocatechin-3-gallate (EGCG) in or on Nanoparticles: Enhanced Stability and Bioavailability of EGCG Encapsulated in Nanoparticles or Targeted Delivery of Gold Nanoparticles Coated with EGCG; Part Two Nanomedicine; Chapter 09 Factors Affecting the Oral Bioavailability of Nanomaterials; Chapter 10 Nanomedicine in Cancer Treatment; Chapter 11 Nanomedicine in Diabetes: Using Nanotechnology in Prevention and Management of Diabetes Mellitus 327 $aChapter 12 Inhalation Pathway as a Promising Portal of Entry: What Has to Be Considered in Designing New Nanomaterials for Biomedical Application?Chapter 13 Nanomedicine for the Brain and the Eye: Disease Management in Poorly Accessible Compartments of the Body; Part Three Stem Cell Toxicology; Chapter 14 Stem Cells in Toxicity Testing; Chapter 15 Human Stem-Cell-Derived Cardiomyocytes in Drug Discovery and Toxicity Testing; Chapter 16 Pluripotent Stem Cells as Tools to Assess Developmental Toxicity: Diversity Instead of Consolidation 327 $aChapter 17 Impact of Various Nanosystems on Stem Cell PhysiologyChapter 18 Predictive Mechanisms in Stem Cells: An In Vitro System-Based Method for Testing Carcinogenicity; Chapter 19 Epigenetic Modifications and Stem Cell Toxicology: Searching for the Missing Link; Chapter 20 Epigenetic Modeling and Stem Cells in Toxicology Testing; Chapter 21 Use of Video Bioinformatics Tools in Stem Cell Toxicology; Author Index; Subject Index 330 $aHandbook of Nanomedicine and Nanotoxicology 606 $aNanoparticles$xToxicology 606 $aNanostructured materials$xToxicology 615 0$aNanoparticles$xToxicology. 615 0$aNanostructured materials$xToxicology. 676 $a615.1901 702 $aSahu$b Saura C. 702 $aCasciano$b Daniel A. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910139117603321 996 $aHandbook of nanotoxicology, nanomedicine and stem cell use in toxicology$91994542 997 $aUNINA